A clinical trial (NCT00780234) designed to assess the ability of pioglitazone to prevent lung cancer in a more general, nondiabetic population has been initiated, and its results may provide additional justification for the application of PPARγ agonists as a chemopreventive strategy against lung cancer. The gene discussed is PPARG; the disease is lung cancer.